



Pergamon

SCIENCE @ DIRECT®

Tetrahedron Letters 44 (2003) 7475–7477

TETRAHEDRON
LETTERS

A versatile method for the synthesis of substituted 1-aminohydantoin derivatives

Iván Bélai*

Plant Protection Institute, Hungarian Academy of Sciences, PO Box 102, H-1525 Budapest, Hungary

Received 13 May 2003; revised 29 July 2003; accepted 8 August 2003

Abstract—An efficient and versatile method has been developed for the synthesis of 1-aminohydantoin derivatives which can be substituted at all the possible positions of the hydantoin ring. The starting materials are aldehydes, ketones, carboxylic acids and hydrazides as well as isocyanates readily available from commercial sources. The semicarbazide-type reaction product of an *N*-acyl-*N'*-(1-cyanoalkyl)hydrazine, obtained from the above materials by methods known from the literature, and an isocyanate is cyclized in the presence of a basic catalyst to yield 1-acylamino-4-imino-2-oxoimidazolidine derivatives whose acid catalyzed hydrolysis leads to 1-aminohydantoin derivatives in good to excellent yields. The last two steps are carried out in a single reaction medium.

© 2003 Elsevier Ltd. All rights reserved.

Although the first 1-aminohydantoin derivatives (1-aminoimidazolidine-2,4-diones) were synthesized at the end of the 19th century¹ no general and versatile route has been developed for the synthesis of 1-aminohydantoin derivatives which can be substituted in any or all of the possible substituent positions. Many publications^{2–5} and patents^{6,7} describe the preparation of 1-aminohydantoin derivatives carrying substituents only in certain positions. Recently a paper has been published describing solid support synthesis of 1-aminohydantoin derivatives.⁸

The significance of the derivatives containing the 1-aminohydantoin core structure is exemplified by several commercially available drugs (Fig. 1), for example the antimicrobial Nitrofurantoin⁹ and the skeletal muscle relaxant Dantrium.¹⁰ The diversity in activity of hydantoin derivatives also bearing 1-methyleneamino groups is shown by two other compounds, Azimilide and BW68C whose activity is different from that of the previously mentioned two compounds. Azimilide is a candidate drug against arrhythmia,¹¹ while BW68C is a potent inhibitor of platelet aggregation acting as an agonist of the prostaglandin D-receptor.¹² The anthelmintic activity of 1-aminohydantoin derivatives bearing a cinnamoyl moiety on the amino function (Fig. 1) has also been reported.¹³

The goal of this work was to develop a simple, general route (Scheme 1) for the synthesis of 1-aminohydantoin derivatives **4** which can bear substituents at all the possible ring positions.




Figure 1.

Keywords: 1-aminohydantoin derivatives; intramolecular cyclization; versatile synthesis method.

* Tel.: +36-1-4877-541; fax: +36-1-4877-555; e-mail: ibel@nki.hu

In summary, we have elaborated a versatile and general method for the synthesis of substituted 1-aminohydantoin derivatives. The semicarbazide-type products **2**, obtained by the addition reaction of an *N*-acyl-*N'*-(1-cyanoalkyl)hydrazine **1** and an isocyanate, were cyclized to yield imino-derivatives **3** which were subsequently hydrolyzed in the same medium to 1-aminohydantoin. For the preparation of hydrazines **1**, a large number of potential starting materials, i.e. aldehydes, ketones, carboxylic acids and hydrazides are available from commercial sources.

References

1. Traube, W.; Hoffa, E. *Chem. Ber.* **1898**, *31*, 162–169.
2. Bailey, J. R.; Read, W. T. *J. Am. Chem. Soc.* **1915**, *37*, 1884–1893.
3. Gut, J.; Novacek, A.; Fiedler, P. *Coll. Czech. Chem. Commun.* **1968**, *33*, 2087–2096.
4. Abou-Ouf, J. *Drug. Res.* **1969**, *2*, 49–54.
5. Milcent, R.; Barbier, G.; Yver, B.; Mazouz, F. *J. Heterocycl. Chem.* **1991**, *28*, 1511–1516.
6. Breuer, H.; Treuner, U. D. US Pat. 1977, 4,038,271.
7. Breuer, H.; Treuner, U. D. Ger. Pat. 1976, 2,714,214.
8. Wilson, L. J.; Li, M.; Portlock, D. E. *Tetrahedron Lett.* **1998**, *39*, 5135–5138.
9. Kenyon, H. US Pat. 1952, 2,610,181.
10. Davis, C. S.; Snyder, H. R. US Pat. 1965, 3,415,821.
11. Yu, C. N.; Pelosi, S. S.; Calcagno, M. A. US Pat. 1994, 5,462,940.
12. Barraclough, P.; Bolofa, M. L.; Giles, H.; Gillam, J.; Harris, C. J.; Kelly, M. G.; Leff, P.; McNeill, A.; Robertson, A. D.; Stepney, R. J.; Whittle, B. J. R. *Bioorg. Med. Chem.* **1996**, *4*, 81–90.
13. Alaimo, H.; Hatton, C. J. *J. Med. Chem.* **1976**, *19*, 349–350.
14. Chi-Tung-Hs, A.; Murphy, R. Eur. Pat. 1987, 234,994.
15. Ziegler, F. E.; Wender, P. A. *J. Org. Chem.* **1977**, *42*, 2001–2003.
16. Chiba, T.; Okimoto, M. *Synthesis* **1990**, 209–211.
17. Karady, S.; Ly, M. G.; Pines, S. H.; Slettinger, M. *J. Org. Chem.* **1971**, *14*, 1946–1948.
18. Ford, M. C.; Rust, R. A. *J. Chem. Soc.* **1958**, 1297–1298.
19. Trivedi, P. B.; Undavia, N. K.; Dave, A. M.; Bhatt, K. M.; Desai, M. C. *Indian J. Chem.* **1993**, *32B*, 497–500.
20. The experimental conditions for the synthesis of 1-aminohydantoins is illustrated by the synthesis of *N*-[3-(4-chlorophenyl)-5,5-dimethyl-2,4-dioximidazolidin-1-yl]-benzamide **4b**: A solution of **1b** ($R^1 = \text{Ph}$, $R^2 = R^3 = \text{Me}$; 2.03 g, 10 mmol) and 4-chlorophenyl isocyanate (1.61 g, 10.5 mmol) in dichloromethane (10 ml) was stirred overnight, then the precipitated product was filtered by suction and washed with dichloromethane to obtain pure **2b** ($R^1 = \text{Ph}$, $R^2 = R^3 = \text{Me}$, $R^4 = 4\text{-ClPh}$). Yield: 73%; mp 164°C. To a suspension of **2b** (1.43 g, 4 mmol) in EtOH (10 ml) was added a solution of 0.2 M NaOEt in EtOH (1 ml, 0.2 mmol). The material dissolved within 2–3 min after which a precipitate appeared. After 2 h, 2N aqueous HCl (4 ml, 8 mmol) was poured into the reaction mixture which was then left at rt for 20 h. The resulting solid material was filtered by suction, washed with water and dried to give **4b** in 95% yield.
21. ^1H NMR (400 MHz, CDCl_3 , TMS) and ^{13}C NMR spectral, as well as elemental analysis data of the new 1-aminohydantoin derivatives.
- 4b**: ^1H NMR: δ 1.55 (s, 6H), 7.40–7.48 (m, 6H), 7.54–7.58 (m, 1H), 7.95–7.97 (m, 2H), 10.21 (s, 1H). ^{13}C NMR: δ 22.08 (2C), 63.37, 127.01 (2C), 127.76 (2C), 128.18 (2C), 128.76 (2C), 129.75, 131.24, 132.21, 133.31, 152.62, 167.40, 173.71. Anal. calcd for $\text{C}_{18}\text{H}_{16}\text{ClN}_3\text{O}_3$: C, 60.43; H, 4.51; N, 11.74; Cl 9.91. Found: C, 60.49; H, 4.43; N, 11.69; Cl, 9.98%.
- 4c**: ^1H NMR: δ 1.51 and 1.54 (2s, 2×3H), 7.25–7.28 (m, 2H), 7.41–7.46 (m, 4H), 7.54–7.57 (m, 1H), 7.65–7.67 (m, 2H), 9.35 (s, 1H). ^{13}C NMR: δ 21.64, 22.81, 64.82, 127.41 (2C), 127.93, 128.49, 128.84, 130.17 (2C), 130.32, 130.70, 131.07, 132.44, 132.93, 153.94, 166.64, 173.47. Anal. calcd for $\text{C}_{18}\text{H}_{16}\text{ClN}_3\text{O}_3$: C, 60.43; H, 4.51; N, 11.74; Cl 9.91. Found: C, 60.51; H, 4.47; N, 11.80, Cl, 9.96%.
- 4d**: ^1H NMR: δ 0.95 and 0.99 (2t, 3H, $J = 7.41$ Hz), 1.49 and 1.52 (2s, 3H), 1.75–1.94 (m, 2H), 3.78 (s, 3H), 6.95–6.99 (m, 1H), 7.15–7.20 (m, 2H), 7.26–7.29 (m, 1H), 7.37–7.46 (m, 3H), 7.54–7.58 (m, 1H). ^{13}C NMR: δ 8.22 and 8.60, 21.23 and 21.44, 28.86 and 29.43, 55.53, 68.90 and 68.99, 111.81 and 111.88, 119.74, 119.85 and 119.91, 128.02 and 128.09, 129.14 and 129.18, 129.71 and 129.73, 130.60 and 130.65, 130.75, 130.96, 131.22 and 131.34, 131.60 and 131.63, 133.00 and 133.59, 154.95 and 155.03, 159.76, 166.64 and 166.74, 173.07 and 173.15. Anal. calcd for $\text{C}_{20}\text{H}_{20}\text{ClN}_3\text{O}_4$: C, 59.78; H, 5.02; N, 10.46; Cl, 8.82. Found: C, 59.69; H, 4.97; N, 10.55; Cl, 8.75%.
- 4e**: ^1H NMR: δ 1.29 (t, 3H, $J = 7.14$ Hz), 1.60–1.78 (m, 6H), 1.84–2.06 (m, 4H), 4.25 (q, 2H, $J = 7.14$ Hz), 7.39–7.40 (m, 5H). ^{13}C NMR: δ 14.38, 21.24 (2C), 24.37, 31.34 (2C), 62.92, 64.04, 127.34 (2C), 129.17 (2C), 129.82, 133.88, 153.48, 156.22, 172.72. Anal. calcd for $\text{C}_{17}\text{H}_{20}\text{ClN}_3\text{O}_4$: C, 55.82; H, 5.51; N, 11.49; Cl, 9.69. Found: C, 55.91; H, 5.47; N, 11.41; Cl, 9.78%.
- 4f**: ^1H NMR: δ 3.12 (s, 3H), 3.79 (s, 3H), 5.35 (s, 1H), 6.91 (d, 2H, $J = 8.89$ Hz), 7.23 (d, 2H, $J = 8.79$ Hz), 7.30–7.34 (m, 2H), 7.48 (m, 2H), 7.68 (dd, 1H, $J = 7.14$ and 1.29 Hz). ^{13}C NMR: δ 25.43, 55.37, 65.45, 114.62 (2C), 124.15, 127.43 (2C), 128.66 (2C), 128.99 (2C), 130.45, 132.75, 157.78, 160.45, 166.61, 170.02. Anal. calcd for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_4$: C, 63.71; H, 5.05; N, 12.38. Found: C, 63.63; H, 4.99; N, 12.31%.
- 4g**: ^1H NMR: δ 1.19–1.43 (m, 6H), 1.40 (s, 6H), 1.66–1.86 (m, 2H), 2.08–2.18 (m, 2H), 3.91–3.99 (m, 1H), 7.27–7.31 (m, 2H), 7.43 (t, 2H, $J = 7.45$ Hz), 7.68 (d, 1H, $J = 7.45$ Hz). ^{13}C NMR: δ 22.06 (2C), 24.91, 25.72 (2C), 29.45 (2C), 51.91, 63.31, 127.32 (2C), 128.48 (2C), 139.51, 132.33, 155.39, 166.74, 175.01. Anal. calcd for $\text{C}_{18}\text{H}_{23}\text{N}_3\text{O}_3$: C, 65.63; H, 7.04; N, 12.76. Found: C, 65.73; H, 6.98; N, 12.84%.
- 4h**: ^1H NMR: δ 0.86 (t, 3H, $J = 7.2$ Hz), 1.22–1.30 (m, 2H), 1.38–1.46 (m, 2H), 3.15–3.20 (m, 2H), 4.58 (brs, 1H), 5.52 (m, 2H), 7.54 (m, 2H), 7.62 (m, 1H), 7.95 (d, 2H, $J = 7.40$ Hz). ^{13}C NMR: δ 13.66, 18.83, 31.89, 36.51, 40.68, 116.30, 127.69 (2C), 128.95 (2C), 130.73, 133.19, 156.51, 166.56. Anal. calcd for $\text{C}_{14}\text{H}_{17}\text{N}_3\text{O}_3$: C, 61.08; H, 6.22; N, 15.26. Found: C, 60.99; H, 6.28; N, 15.34%.
- 4i**: ^1H NMR: δ 1.49 (s, 9H), 1.50 (s, 6H), 6.65 (brs, 1H), 7.40 (s, 4H). ^{13}C NMR: δ 22.11 (2C), 28.04 (3C), 62.97, 82.71, 127.15 (2C), 129.15 (2C), 129.89, 133.86, 146.73, 154.91, 173.64. Anal. calcd for $\text{C}_{16}\text{H}_{20}\text{ClN}_3\text{O}_4$: C, 54.32; H, 5.70; N, 11.88; Cl, 10.02. Found: C, 54.41; H, 5.75; N, 11.81; Cl, 9.95%.